Design (Testphase)
Growth
Matt Caruso: Sales Leader
25
Hits
August 3, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Matt Caruso's sales screen: 12-month relative strength above 75, revenue growth in the latest quarter above 40%, 12-month revenue growth above 40%, price above $20, and average volume (50 days) above 150,000 shares — market leaders whose growth is accelerating AND that the market is already rewarding. Source: fundamental data.
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names after a reverse split (distorted price history) and names with a red Stress RS (rating ≤ 30 — weak on stress days) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(15)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth TickerGuard company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from 0 to 100 points with a school-grade rank from A+ to F. 50 points is the average across the universe, 100 the best possible score. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below — A/A+ are the fundamentally strongest stocks in the universe.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Growth Score | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AAOI Applied Optoelectronics, Inc. | 08/06 | +1,099 % | 92 10/25 | Stage 2 | B 62 | 4 of 9 | 7.6 $ | Communication Equipment | Sells AI | — | — | Technology | 94.30 $ | +322.9 % | +266.1 % | +312.4 % | −40.7 % | +59.4 % | 98 | 42 | 12.0 % | 12.7 % | 3.69 | — | 84.0 | 14.9 | 6.9 | — | 0.78 | 38.4 | -8.6 % | 29.6 % | -8.6 % | -6.1 % | -3.3 % | 0.16 | 70.6 % | +82.8 % | — | 0.0 % | 0.0 % | 7.6 | 68.3 % | 12.9 % | 4.2 (5) |
| LQDA Liquidia Technologies Inc | 08/11 | +241 % | 93 9/22 | Stage 2 | A 75 | 7 of 9 | 7.5 $ | Drug Manufacturers - Specialty & Generic | Neutral | — | — | Healthcare | 84.10 $ | +114.7 % | +109.9 % | +350.0 % | −1.7 % | +0.9 % | 98 | 42 | 6.2 % | 6.4 % | 0.55 | 502.7 | 21.2 | 26.0 | 70.0 | 181.4 | — | 138.3 | 46.3 % | 91.8 % | 7.7 % | 28.2 % | 9.0 % | 1.70 | 27.0 % | +1,031.2 % | — | 0.0 % | 0.0 % | 2.9 | 70.2 % | 17.2 % | 4.3 (10) |
| CRDO Credo Technology Group Holding Ltd | 09/02 | +487 % | 72 7/25 | Stage 2 | A 87 | 7 of 9 | 38.5 $ | Semiconductors | Sells AI | — | Technology | 207.00 $ | +89.0 % | +63.6 % | +85.6 % | −13.2 % | +34.9 % | 96 | 93 | 10.5 % | 11.3 % | 3.20 | 83.7 | 35.1 | 28.8 | 18.8 | 94.6 | — | 77.5 | 35.7 % | 68.0 % | 35.4 % | 34.4 % | 17.9 % | 0.01 | 89.9 % | +205.7 % | — | 0.0 % | 0.0 % | 19.7 | 75.9 % | 3.6 % | 4.6 (13) | |
| TVTX Travere Therapeutics Inc | 08/05 | +82 % | 68 6/22 | Stage 2 | B 64 | 5 of 9 | 5.1 $ | Biotechnology | Uses AI | — | Healthcare | 55.90 $ | +46.4 % | +44.7 % | +261.8 % | −1.8 % | +5.8 % | 96 | 42 | 3.6 % | 4.6 % | 1.11 | — | 76.3 | 9.5 | 51.5 | 292.4 | — | 136.5 | -29.0 % | 56.0 % | -4.0 % | -69.4 % | -6.5 % | 3.35 | 17.8 % | +110.5 % | — | 0.0 % | 0.0 % | -2.7 | 113.4 % | 16.9 % | 4.6 (15) | |
| SITM Sitime Corporation | 08/05 | +172 % | 72 7/25 | Stage 2 | A 77 | 7 of 9 | 15.1 $ | Semiconductors | Sells AI | — | — | Technology | 535.20 $ | +100.1 % | +87.9 % | +163.8 % | −25.1 % | +56.5 % | 95 | 12 | 8.0 % | 7.5 % | 2.91 | — | 71.9 | 39.6 | 12.1 | 278.7 | 3.82 | 3,076.2 | -4.2 % | 55.7 % | -6.4 % | -2.6 % | -2.3 % | 0.00 | 89.6 % | +61.2 % | — | 0.0 % | 0.0 % | 16.1 | 89.0 % | 5.0 % | 3.9 (7) |
| SEPN Septerna, Inc. Common Stock | 08/10 | — | — | Stage 2 | C 48 | 4 of 9 | 0.0 $ | Biotechnology | – | — | — | Healthcare | 34.50 $ | +31.2 % | +17.9 % | +177.6 % | −9.1 % | +30.3 % | 94 | 50 | 7.5 % | 6.9 % | — | — | 107.5 | — | — | — | — | 0.0 | — | 100.0 % | -49.9 % | -9.3 % | -8.5 % | — | — | +4,174.5 % | — | 0.0 % | 0.0 % | 7.0 | 102.7 % | 11.7 % | — |
| OUST Ouster, Inc. Common Stock | 08/06 | +244 % | 61 6/25 | Stage 2 | B 58 | 6 of 9 | 2.6 $ | Electronic Components | Sells AI | — | Technology | 39.00 $ | +108.7 % | +141.8 % | +66.9 % | −18.8 % | +33.7 % | 93 | 42 | 15.3 % | 13.5 % | 3.18 | — | 0.0 | 14.2 | — | — | — | -0.8 | -39.6 % | 47.7 % | -30.1 % | -25.2 % | -14.7 % | — | 72.2 % | +52.5 % | — | 0.0 % | 0.0 % | -0.7 | 50.0 % | 9.3 % | 4.3 (6) | |
| SEI Solaris Energy Infrastructure, Inc | 07/22 | +327 % | 79 3/10 | Stage 2 | B 73 | 5 of 9 | 5.1 $ | Oil & Gas Equipment & Services | Sells AI | — | Energy | 51.40 $ | +70.3 % | +76.6 % | +59.0 % | −7.8 % | +83.5 % | 92 | 87 | 7.0 % | 7.1 % | 1.18 | — | 384.6 | 7.3 | — | — | 0.94 | 20.2 | 25.8 % | 46.9 % | 6.7 % | 8.7 % | 5.0 % | — | 26.1 % | +98.7 % | — | 0.9 % | 66.7 % | 4.1 | 113.1 % | 26.1 % | 4.9 (8) | |
| AXSM Axsome Therapeutics Inc | 08/03 | +58 % | 78 7/22 | Stage 2 | B 55 | 5 of 9 | 11.6 $ | Biotechnology | – | — | — | Healthcare | 218.00 $ | +32.5 % | +56.9 % | +115.0 % | −8.8 % | +29.5 % | 92 | 42 | 3.6 % | 3.5 % | 0.60 | — | 333.3 | 16.3 | 205.5 | — | — | -14.8 | -32.8 % | 92.6 % | -26.6 % | -349.4 % | -16.8 % | 4.03 | 7.6 % | +65.6 % | — | 0.0 % | 0.0 % | -3.1 | 76.6 % | 9.2 % | 4.7 (19) |
| ETON Eton Pharmaceuticals Inc | 08/06 | +249 % | 96 10/22 | Stage 2 | B 55 | 7 of 9 | 1.3 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 46.40 $ | +98.0 % | +116.2 % | +227.8 % | −2.4 % | +18.0 % | 92 | 26 | 4.8 % | 5.7 % | 0.86 | — | 52.6 | 14.7 | 42.5 | 82.9 | — | 206.8 | — | 59.7 % | -1.7 % | -5.4 % | 4.8 % | 0.40 | — | +104.9 % | — | 0.0 % | 0.0 % | 0.7 | 65.4 % | 6.3 % | 4.7 (3) |
| UMAC Unusual Machines, Inc. | 08/13 | — | 83 8/25 | Stage 2 | C 52 | 3 of 9 | 1.0 $ | Computer Hardware | Neutral | — | Technology | 21.20 $ | +56.4 % | +30.8 % | +129.0 % | −40.4 % | +64.4 % | 92 | 42 | 10.2 % | 15.0 % | 14.79 | — | 67.6 | 60.9 | 3.0 | — | — | 0.0 | -89.7 % | 35.2 % | -32.7 % | -3.3 % | -10.2 % | 0.00 | 95.8 % | +101.2 % | — | 0.0 % | 0.0 % | 76.3 | 60.2 % | 19.7 % | 4.7 (3) | |
| ASTH Astrana Health Inc | 08/06 | +13 % | 70 6/22 | Stage 2 | B 62 | 5 of 9 | 1.8 $ | Medical Care Facilities | Uses AI | — | Healthcare | 35.60 $ | +66.1 % | +79.3 % | +49.0 % | −0.5 % | +38.6 % | 89 | 87 | 3.6 % | 3.8 % | 0.89 | — | 23.0 | 0.5 | — | 11.4 | — | 14.4 | 3.0 % | 10.7 % | 0.9 % | 5.7 % | 3.6 % | — | 33.9 % | +56.4 % | — | 0.0 % | 0.0 % | 5.2 | 61.5 % | 10.3 % | 4.5 (12) | |
| CYTK Cytokinetics Inc | 08/06 | +8 % | 68 6/22 | Stage 2 | D 39 | 3 of 9 | 10.4 $ | Biotechnology | Neutral | — | Healthcare | 77.10 $ | +25.9 % | +36.0 % | +104.9 % | −2.6 % | +39.8 % | 88 | 42 | 4.6 % | 4.1 % | 0.42 | — | 117.6 | 97.8 | 57.5 | — | — | -15.8 | -948.7 % | -290.7 % | 0.0 % | -572.2 % | -31.5 % | -1.56 | -64.9 % | +376.6 % | — | 0.0 % | 0.0 % | -7.3 | 118.8 % | 19.4 % | 4.3 (21) | |
| CGON CG Oncology, Inc. Common stock | 08/14 | — | 68 6/22 | Stage 2 | C 51 | 4 of 9 | 6.3 $ | Biotechnology | – | — | — | Healthcare | 71.20 $ | +58.3 % | +83.7 % | +166.7 % | −3.5 % | +27.4 % | 88 | 42 | 6.2 % | 5.5 % | 0.22 | — | 0.0 | 1,240.6 | 5.8 | — | — | 0.0 | -6,130.1 % | -2,670.9 % | 0.0 % | -20.8 % | -14.4 % | 0.01 | 96.2 % | +254.7 % | — | 0.0 % | 0.0 % | 33.4 | 109.9 % | 14.0 % | 4.4 (10) |
| MIRM Mirum Pharmaceuticals Inc | 08/05 | +102 % | 68 6/22 | Stage 2 | C 45 | 3 of 9 | 6.3 $ | Biotechnology | – | — | — | Healthcare | 106.00 $ | +40.6 % | +52.3 % | +105.0 % | −1.9 % | +38.2 % | 86 | 42 | 5.0 % | 5.0 % | 0.49 | — | 39.7 | 11.0 | 28.1 | — | — | 341.2 | -39.5 % | 81.4 % | -140.2 % | -335.8 % | -5.9 % | 1.34 | 27.2 % | +54.7 % | — | 0.0 % | 0.0 % | -5.4 | 114.4 % | 15.6 % | 4.6 (10) |
| FTAI FTAI Aviation Ltd. | 08/04 | +283 % | 76 9/29 | Stage 2 | B 68 | 5 of 9 | 21.0 $ | Aerospace & Defense | – | — | — | Industrials | 206.00 $ | +33.6 % | +52.7 % | +50.9 % | −17.0 % | +82.8 % | 83 | 77 | 6.6 % | 6.4 % | 1.51 | 41.0 | 28.5 | 6.8 | 49.0 | — | 3.22 | 22.2 | 22.5 % | 32.2 % | 15.9 % | 233.3 % | 11.4 % | 10.23 | 9.5 % | +43.2 % | — | 1.0 % | 34.1 % | 8.0 | 97.2 % | 10.6 % | 4.5 (13) |
| BEAM Beam Therapeutics Inc | 08/04 | +2 % | 39 4/22 | Stage 2 | C 53 | 4 of 9 | 2.7 $ | Biotechnology | – | — | — | Healthcare | 25.50 $ | +19.8 % | +24.2 % | +29.5 % | −8.0 % | +105.1 % | 83 | 42 | 7.7 % | 7.2 % | 2.18 | — | 0.0 | 16.3 | 2.2 | — | — | -7.0 | -337.8 % | -146.9 % | -40.2 % | -5.8 % | -15.8 % | 0.22 | 78.6 % | +120.0 % | — | 0.0 % | 0.0 % | 8.3 | 107.0 % | 35.0 % | 4.4 (17) |
| ARQT Arcutis Biotherapeutics Inc | 08/05 | +66 % | 54 5/22 | Stage 3 | B 65 | 6 of 9 | 3.4 $ | Biotechnology | – | — | — | Healthcare | 26.90 $ | -9.5 % | -9.1 % | +84.2 % | −16.0 % | +28.7 % | 77 | 42 | 4.7 % | 4.6 % | 1.48 | — | 149.3 | 8.2 | 17.9 | 127.3 | — | 226.7 | -8.6 % | 90.9 % | -0.6 % | -1.4 % | 0.5 % | 0.07 | 41.2 % | +91.3 % | — | 0.0 % | 0.0 % | -0.1 | 110.2 % | 11.6 % | 4.6 (7) |
| PTCT PTC Therapeutics Inc | 08/06 | +33 % | 68 6/22 | Stage 2 | C 53 | 2 of 9 | 5.6 $ | Biotechnology | – | — | — | Healthcare | 68.00 $ | +8.1 % | +4.1 % | +30.5 % | −3.4 % | +42.5 % | 75 | 42 | 4.7 % | 4.0 % | 0.53 | — | 35.6 | 5.6 | 1,402.7 | — | 0.81 | 23.9 | 16.5 % | 50.0 % | -3.8 % | -7,740.1 % | 2.5 % | -2.19 | -6.3 % | +114.5 % | — | 0.0 % | 0.0 % | 2.5 | 117.7 % | 16.1 % | 3.9 (14) |
| IDR Idaho Strategic Resources Inc | 08/06 | +168 % | — | Stage 1 | A 77 | 7 of 9 | 0.0 $ | Gold | Neutral | — | Basic Materials | 28.10 $ | -18.9 % | -31.5 % | +71.2 % | −40.5 % | +38.3 % | 72 | 50 | 8.4 % | 8.0 % | 1.21 | 23.3 | 22.0 | — | 4.5 | — | — | 18.9 | — | 69.7 % | 43.3 % | 26.5 % | 15.7 % | 0.02 | — | +64.6 % | — | 0.0 % | 0.0 % | 25.9 | 46.7 % | 8.0 % | — | |
| RYTM Rhythm Pharmaceuticals Inc | 08/04 | +170 % | 39 4/22 | Stage 3 | B 57 | 5 of 9 | 6.7 $ | Biotechnology | – | — | — | Healthcare | 99.30 $ | -0.8 % | -2.0 % | +16.5 % | −11.4 % | +39.8 % | 70 | 42 | 5.8 % | 4.8 % | 1.88 | — | 0.0 | 31.0 | 55.4 | — | — | -12.6 | -87.1 % | 89.4 % | -93.3 % | -101.2 % | -29.8 % | 1.85 | 27.8 % | +45.8 % | — | 0.0 % | 0.0 % | -4.6 | 110.0 % | 14.1 % | 4.7 (12) |
| MDGL Madrigal Pharmaceuticals Inc | 08/04 | +39 % | 78 7/22 | Stage 2 | B 57 | 2 of 9 | 10.9 $ | Biotechnology | – | — | — | Healthcare | 467.30 $ | -11.8 % | -12.5 % | +54.5 % | −16.5 % | +46.1 % | 68 | 42 | 4.0 % | 4.0 % | -1.06 | — | 666.7 | 8.5 | 19.8 | — | — | -8.3 | -29.8 % | 91.5 % | -25.3 % | -49.4 % | -17.8 % | 0.64 | 44.3 % | +432.1 % | — | 0.0 % | 0.0 % | 1.3 | 106.5 % | 10.5 % | 4.5 (15) |
| ASTS Ast Spacemobile Inc | 08/10 | +321 % | 87 9/25 | Stage 1 | C 54 | 5 of 9 | 23.0 $ | Communication Equipment | – | — | — | Technology | 59.00 $ | +0.3 % | +11.2 % | +10.9 % | −51.0 % | +36.4 % | 62 | 42 | 10.4 % | 11.6 % | 2.68 | — | 0.0 | 270.9 | 8.8 | — | — | -2.3 | -1,014.0 % | 44.8 % | 0.0 % | -37.8 % | -6.3 % | 1.44 | 34.4 % | +1,505.2 % | — | 0.0 % | 0.0 % | 5.9 | 47.2 % | 19.9 % | 3.2 (11) |
| BBIO BridgeBio Pharma Inc | 08/04 | +113 % | 68 6/22 | Stage 1 | C 54 | 3 of 9 | 15.7 $ | Biotechnology | – | — | — | Healthcare | 80.10 $ | -10.3 % | -5.9 % | +69.4 % | −18.0 % | +31.4 % | 59 | 42 | 3.7 % | 4.0 % | 0.95 | — | 0.0 | 27.0 | 142.2 | — | — | -9.4 | -54.5 % | 95.1 % | -124.4 % | -1,789.7 % | -28.0 % | -1.49 | -165.5 % | +126.3 % | — | 0.0 % | 0.0 % | -7.9 | 103.2 % | 14.7 % | 4.4 (19) |
| BETR Better Home & Finance Holding Company | 08/12 | -33 % | — | Stage 4 | D 42 | 3 of 9 | 0.0 $ | Mortgage Finance | – | — | — | Financial Services | 23.50 $ | -21.1 % | -28.2 % | +81.6 % | −72.8 % | +61.1 % | 40 | 50 | 9.0 % | 8.7 % | 1.73 | — | 0.0 | — | — | — | — | -0.9 | — | 100.0 % | -102.5 % | -875.5 % | -13.2 % | — | — | +59.4 % | — | 0.0 % | 0.0 % | -1.0 | 46.6 % | 23.1 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Matt Caruso's sales screen: 12-month relative strength above 75, revenue growth in the latest quarter above 40%, 12-month revenue growth above 40%, price above $20, and average volume (50 days) above 150,000 shares — market leaders whose growth is accelerating AND that the market is already rewarding. Source: fundamental data.
All scanners are recalculated daily across the entire stock universe — most recently on 3. August 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 25 stocks pass this scanner's criteria (as of 3. August 2026).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names after a reverse split (distorted price history) and names with a red Stress RS (rating ≤ 30 — weak on stress days) are excluded.
Related scanners
- Ben Bennett: Focus List
- Ben Bennett: Power Screen
- Dan Zanger: Leader
- EPS & Revenue Power
- EPS Acceleration
- High Revenue Growth
- Jim Roppel: 20/20 Screen
- Joshua
- Martin Zweig: Growth with Reason
- Patrick Walker: 30% EPS Growth
- Patrick Walker: 40, 40 Screen
- Quality Growth
- Small Caps with Growth
- Ted Zhang: Super Stock Universe
- Thomas' Favorites
- Triple-Digit Revenue Growth
- William O'Neil (CAN SLIM)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.